| Literature DB >> 28283889 |
Rikiya Taoka1, Goodwin G Jinesh2, Wenrui Xue1, Stephen Safe3, Ashish M Kamat4.
Abstract
Cancer stem cells are capable of undergoing cellular transformation after commencement of apoptosis through the blebbishield emergency program in a VEGF-VEGFR2-dependent manner. Development of therapeutics targeting the blebbishield emergency program would thus be important in cancer therapy. Specificity protein 1 (Sp1) orchestrates the transcription of both VEGF and VEGFR2; hence, Sp1 could act as a therapeutic target. Here, we demonstrate that CF3DODA-Me induced apoptosis, degraded Sp1, inhibited the expression of multiple drivers of the blebbishield emergency program such as VEGFR2, p70S6K, and N-Myc through activation of caspase-3, inhibited reactive oxygen species; and inhibited K-Ras activation to abolish transformation from blebbishields as well as transformation in soft agar. These findings confirm CF3DODA-Me as a potential therapeutic candidate that can induce apoptosis and block transformation from blebbishields.Entities:
Keywords: Blebbishields; Cellular transformation; K-Ras; Sp1; VEGFR2
Mesh:
Substances:
Year: 2017 PMID: 28283889 DOI: 10.1007/s10495-017-1359-1
Source DB: PubMed Journal: Apoptosis ISSN: 1360-8185 Impact factor: 4.677